Loading
Radiomics and Machine Learning in Medical Imaging / Colorectal Cancer Treatments and Studies · Journal article
Frontiers in Oncology · August 12, 2026
Encouraging direction, but not yet definitive.
In a single-centre retrospective cohort of 262 advanced NSCLC patients, cutaneous irAE independently predicted improved overall survival with a time-dependent hazard ratio of 0.52 (95% CI 0.35–0.78; P=0.002) using appropriate statistical methods to correct for immortal time bias. An exploratory grade-stratified analysis suggested a severity-associated gradient, with grade 3+ cirAE associated with median OS of 47.7 months versus 18.8 months for no cirAE, but the grade 3+ group was small (n=21) and the authors characterize this finding as hypothesis-generating pending prospective validation.
Retrospective cohort study with time-dependent Cox regression and landmark analysis. Advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors; study conducted at a single institution.. Intervention: Cutaneous immune-related adverse events (cirAE) during ICI therapy. Compared with: No cutaneous immune-related adverse events. n = 262. Single institution (location not specified in source).
Multivariable time-dependent Cox analysis showed cirAE independently associated with improved OS (HR = 0.52; 95% CI: 0.35–0.78; P = 0.002) No time-invariant PFS association observed (HR = 0.91; P = 0.586); time-varying analysis revealed early PFS hazard reduction attenuating over follow-up Grade-stratified exploratory analysis: grade 1–2 cirAE HR = 0.51 (P = 0.001) and grade 3+ cirAE HR = 0.33 (P = 0.003); median OS 18.8, 36.1, and 47.7 months for no cirAE, grade 1–2, and grade 3+ groups respectively (P for trend 0.001)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated prospectively, cutaneous irAE could serve as an early, accessible surrogate signal of ICI efficacy in advanced NSCLC, potentially guiding treatment continuation and dermatologic management. The apparent dose–response relationship between cirAE severity and OS benefit warrants formal prospective investigation and should not yet guide treatment decisions without additional evidence.
Retrospective cohort study with rigorous time-dependent Cox analysis addressing immortal time bias, demonstrating independent OS benefit of cutaneous irAE in advanced NSCLC, but single-institution design and small grade 3+ subgroup limit immediate generalizability.
As stated by the source record.
Quoted from the source exactly as published.
If validated prospectively, cutaneous irAE could serve as an early, accessible surrogate signal of ICI efficacy in advanced NSCLC, potentially guiding treatment continuation and dermatologic management. The apparent dose–response relationship between cirAE severity and OS benefit warrants formal prospective investigation and should not yet guide treatment decisions without additional evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction Cutaneous immune-related adverse events (cirAE) affect up to 34% of patients receiving immune checkpoint inhibitor (ICI) therapy, yet their prognostic significance in advanced non-small cell lung cancer (NSCLC) remains disputed. A key methodological flaw in the existing literature is immortal time bias, which inflates the apparent benefit of cirAE in conventional analyses. Methods We conducted a retrospective cohort study of 262 advanced NSCLC patients treated with ICIs at a single institution between January 2021 and January 2025. Patients were classified into cirAE (n=80) and no cirAE (n=182) groups. Time-dependent Cox regression was the primary analysis to address immortal time bias; landmark analysis at 2.2 months (the median cirAE onset) served as a supportive analysis. The primary endpoint was overall survival (OS); progression-free survival (PFS) was secondary. Results In multivariable time-dependent Cox analysis, cirAE was independently associated with improved OS (HR = 0.52; 95% CI: 0.35–0.78; P = 0.002). No time-invariant PFS association was observed (HR = 0.91; P = 0.586); a complementary time-varying analysis revealed an early PFS hazard reduction that attenuated over follow-up, consistent with detection bias from more intensive surveillance in cirAE patients. The OS association was consistent across all prespecified subgroups (all P for interaction 0.05), and was confirmed in a sensitivity analysis re-including patients with concurrent non-cutaneous irAE (HR = 0.56; P = 0.002).An exploratory grade-stratified analysis suggested a severity-associated trend: grade 1–2 (HR = 0.51; P = 0.001) and grade 3+ cirAE (HR = 0.33; P = 0.003) showed progressively lower OS hazard estimates (P for trend 0.001; median OS: 18.8, 36.1, and 47.7 months for no cirAE, grade 1–2, and grade 3+ groups, respectively). Discussion Given the small grade 3+ subgroup (n=21), these findings should be considered hypothesis-generating. cirAE may serve as an early, accessible signal of ICI efficacy in NSCLC. The exploratory severity-outcome gradient suggests that high-grade cirAE may identify patients deriving the greatest benefit from continued ICI therapy under appropriate dermatologic management, pending prospective validation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.